Mereo BioPharma Group (MREO) Revenue & Revenue Breakdown
Mereo BioPharma Group Revenue Highlights
Latest Revenue (Y)
$10.00M
Mereo BioPharma Group Revenue by Period
Mereo BioPharma Group Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $10.00M | 563.57% |
| 2022-12-31 | $1.51M | -95.87% |
| 2021-12-31 | $36.46M | 9178.37% |
| 2020-12-31 | $393.00K | -422.13% |
| 2019-12-31 | $-122.00K | 100.00% |
| 2018-12-31 | - | -100.00% |
| 2017-12-31 | $-3.29M | 100.00% |
| 2016-12-31 | - | - |
Mereo BioPharma Group generated $10.00M in revenue during NA 2023, up 563.57% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Mereo BioPharma Group Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $361.10K | -32.31% |
| 2023-09-30 | $533.43K | -93.93% |
| 2023-06-30 | $8.79M | 146.64% |
| 2023-03-31 | $3.56M | 328.36% |
| 2022-12-31 | $832.01K | 23.26% |
| 2022-09-30 | $674.99K | 100.00% |
| 2022-06-30 | - | -100.00% |
| 2022-03-31 | $462.39K | 100.00% |
| 2021-12-31 | - | -100.00% |
| 2021-09-30 | $308.58K | -99.39% |
| 2021-06-30 | $50.64M | 101.49% |
| 2021-03-31 | $25.13M | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | - |
Mereo BioPharma Group generated - in revenue during Q1 2024, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Mereo BioPharma Group Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| AMLX | Amylyx Pharmaceuticals | $380.79M | $88.64M |
| HOOK | HOOKIPA Pharma | $20.13M | - |
| MREO | Mereo BioPharma Group | $10.00M | - |
| XFOR | X4 Pharmaceuticals | - | $563.00K |
| PDSB | PDS Bio | - | - |
| DAWN | Day One Biopharmaceuticals | - | $8.19M |
| ABOS | Acumen Pharmaceuticals | - | - |
| INZY | Inozyme Pharma | - | - |
| ELEV | Elevation Oncology | - | - |
| TERN | Terns Pharmaceuticals | - | - |
| HEPA | Hepion Pharmaceuticals | - | - |
| EFTR | eFFECTOR Therapeutics | - | - |
MREO Revenue FAQ
What is Mereo BioPharma Group’s yearly revenue?
Mereo BioPharma Group's yearly revenue for 2023 was $10M, representing an increase of 563.57% compared to 2022. The company's yearly revenue for 2022 was $1.51M, representing a decrease of -95.87% compared to 2021. MREO's yearly revenue for 2021 was $36.46M, representing an increase of 9178.37% compared to 2020.
What is Mereo BioPharma Group’s quarterly revenue?
Mereo BioPharma Group's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a -100.00% decrease year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $361.1K, a -32.31% decrease from the previous quarter (Q3 2023), and a -56.60% decrease year-over-year (Q4 2022). MREO's quarterly revenue for Q3 2023 was $533.43K, a -93.93% decrease from the previous quarter (Q2 2023), and a -20.97% decrease year-over-year (Q3 2022).
What is Mereo BioPharma Group’s revenue growth rate?
Mereo BioPharma Group's revenue growth rate for the last 3 years (2021-2023) was -72.58%, and for the last 5 years (2019-2023) was -8296.72%.